⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XBIO News
Xenetic Biosciences, Inc.
Form 8-K
sec.gov
XBIO
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
accessnewswire.com
XBIO
Form 8-K
sec.gov
XBIO
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
accessnewswire.com
XBIO
Form 8-K
sec.gov
XBIO
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
accessnewswire.com
XBIO
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
accessnewswire.com
XBIO
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
accessnewswire.com
XBIO
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
accessnewswire.com
XBIO
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
accessnewswire.com
XBIO